Effect of linagliptin on vascular function: A randomized, placebo-controlled study

Journal of Clinical Endocrinology and Metabolism

Volumn 101, Issue 11, 2016, Pages 4205-4213

  Baltzis, Dimitrios ^a   Dushay, Jody R ^a   Loader, Jordan ^a   Wu, Jim ^a   Greenman, Robert L ^a   Roustit, Matthieu ^a   Veves, Aristidis ^a  

^a BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GAMMA INTERFERON; GROWTH FACTOR; INTERLEUKIN 12; INTERLEUKIN 6; LINAGLIPTIN; PHOSPHORUS 31; PLACEBO; DIPEPTIDYL PEPTIDASE IV INHIBITOR;

ABSENCE OF SIDE EFFECTS; ADULT; AGED; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DISORDERS OF MITOCHONDRIAL FUNCTIONS; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; ENDOTHELIAL PROGENITOR CELL; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; IONTOPHORESIS; MAJOR CLINICAL STUDY; MALE; METABOLITE; NERVE FIBER; NON INSULIN DEPENDENT DIABETES MELLITUS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TERTIARY HEALTH CARE; VASODILATATION; BLOOD; DIABETES MELLITUS, TYPE 2; DIAGNOSTIC IMAGING; MIDDLE AGED; MITOCHONDRIAL DISEASES; OUTCOME ASSESSMENT; VASCULAR DISEASES;

AGED; DIABETES MELLITUS, TYPE 2; DIPEPTIDYL-PEPTIDASE IV INHIBITORS; FEMALE; HUMANS; LINAGLIPTIN; MALE; MIDDLE AGED; MITOCHONDRIAL DISEASES; OUTCOME ASSESSMENT (HEALTH CARE); VASCULAR DISEASES;

EID: 84994851691     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2016-2655     Document Type: Article

References (35)

1. American Diabetes Association. Standards of Medical Care in Diabetes. Diabetes Care. 2016;39.
2. Ban K, Noyan-Ashraf MH, Hoefer J, Bolz SS, Drucker DJ, Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and-independent pathways. Circulation. 2008; 117:2340-2350.
3. Ussher JR, Drucker DJ. Cardiovascular actions of incretin-based therapies. Circ Res. 2014;114:1788-1803.
4. Zhong J, Maiseyeu A, Davis SN, Rajagopalan S. DPP4 in cardiometabolic disease recent insights from the laboratory and clinical trials of DPP4 inhibition. Circ Res. 2015;116:1491-1504.
5. Matsubara J, Sugiyama S, Sugamura K, et al. A dipeptidyl peptidase-4 inhibitor, des-fluoro-sitagliptin, improves endothelial function and reduces atherosclerotic lesion formation in apolipoprotein E-deficient mice. J Am Coll Cardiol. 2012;59:265-276.
6. Scirica BM, Bhatt DL, Braunwald E, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med. 2013;369:1317-1326.
7. Green JB, Bethel MA, Armstrong PW, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015; 373:232-242.
8. White WB, Cannon CP, Heller SR, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369:1327-1335.
9. Scirica BM, Braunwald E, Raz I, et al. Heart failure, saxagliptin, and diabetes mellitus: Observations from the SAVOR-TIMI 53 randomized trial. Circulation. 2014;130:1579-1588.
10. Zannad F, Cannon CP, Cushman WC, et al. Heart failure and mortality outcomes in patients with type 2 diabetes taking alogliptin versus placebo in EXAMINE: A multicentre, randomised, doubleblind trial. The Lancet. 2015;385:2067-2076.
11. Ayaori M, Iwakami N, Uto-Kondo H, et al. Dipeptidyl Peptidase-4 Inhibitors Attenuate Endothelial Function as Evaluated by Flow-Mediated Vasodilatation in Type 2 Diabetic Patients. J Am Heart Assoc. 2013;2:e003277.
12. Kubota Y, MiyamotoM,Takagi G, et al. The dipeptidyl peptidase-4 inhibitor sitagliptin improves vascular endothelial function in type 2 diabetes. J Korean Med Sci. 2012;27:1364-1370.
13. Leung M, Leung DY, Wong VW. Effects of dipeptidyl peptidase-4 inhibitors on cardiac and endothelial function in type 2 diabetes mellitus: A pilot study. Diab Vasc Dis Res. 2016;13:236-243.
14. Nakamura K, Oe H, Kihara H, et al. DPP-4 inhibitor and alphaglucosidase inhibitor equally improve endothelial function in patients with type 2 diabetes:EDGEstudy. Cardiovasc Diabetol. 2014; 13:110.
15. Noda Y, Miyoshi T,OeH, et al. Alogliptin ameliorates postprandial lipemia and postprandial endothelial dysfunction in non-diabetic subjects: A preliminary report. Cardiovasc Diabetol. 2013;12:8.
16. Kroller-Schon S, Knorr M, Hausding M, et al. Glucose-independent improvement of vascular dysfunction in experimental sepsis by dipeptidyl peptidase-4 inhibition. Cardiovasc Res. 2012;96:140-149.
17. Petersen KF, Dufour S, Befroy D, Garcia R, Shulman GI. Impaired mitochondrial activity in the insulin-resistant offspring of patients with type 2 diabetes. N Engl J Med. 2004;350:664-671.
18. Kelley DE, He J, Menshikova EV, Ritov VB. Dysfunction of mitochondria in human skeletal muscle in type 2 diabetes. Diabetes. 2002;51:2944-2950.
19. Petersen KF, Shulman GI. Etiology of insulin resistance. Am J Med. 2006;119:S10-S16.
20. Tecilazich F, Dinh T, Lyons TE, et al. Postexercise phosphocreatine recovery, an index of mitochondrial oxidative phosphorylation, is reduced in diabetic patients with lower extremity complications. J Vasc Surg. 2013;57:997-1005.
21. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003;26 Suppl 1:S5-S20.
22. Gore JC. Principles and practice of functional MRI of the human brain. J Clin Invest. 2003;112:4-9.
23. Roustit M, Cracowski JL. Assessment of endothelial and neurovascular function in human skin microcirculation. Trends Pharmacol Sci. 2013;34:373-384.
24. Dinh T, Tecilazich F, Kafanas A, et al. Mechanisms involved in the development and healing of diabetic foot ulceration. Diabetes. 2012;61:2937-2947.
25. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: A report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol. 2002;39: 257-265.
26. Tecilazich F, Dinh T, Pradhan-Nabzdyk L, et al. Role of endothelial progenitor cells and inflammatory cytokines in healing of diabetic foot ulcers. PLoS One. 2013;8:e83314.
27. Forst T, Michelson G, Diessel S, Jahnke J, Kapitza C. Microvascular effects of the inhibition of dipeptidylpeptidase IV by linagliptin in nondiabetic hypertensive patients. J Hypertens. 2016;34:345-350.
28. Ott C, Raff U, Schmidt S, et al. Effects of saxagliptin on early microvascular changes in patients with type 2 diabetes. Cardiovasc Diabetol. 2014;13:19.
29. Ussher JR, Drucker DJ. Cardiovascular biology of the incretin system. Endocr Rev. 2012;33:187-215.
30. Fadini GP, Bonora BM, Cappellari R, et al. Acute effects of linagliptin on progenitor cells, monocyte phenotypes, and soluble mediators in type 2 diabetes. J Clin Endocrinol Metab. 2016;101:748-756.
31. Werner N, Kosiol S, Schiegl T, et al. Circulating endothelial progenitor cells and cardiovascular outcomes. N Engl J Med. 2005; 353:999-1007.
32. Rigato M, Avogaro A, Fadini GP. Levels of circulating progenitor cells, cardiovascular outcomes and death: A meta-analysis of prospective observational studies. Circ Res. 2016;118:1930-1939.
33. Harris RA, Nishiyama SK, Wray DW, Richardson RS. Ultrasound assessment of flow-mediated dilation. Hypertension. 2010;55: 1075-1085.
34. Thijssen DH, Black MA, Pyke KE, et al. Assessment of flow-mediated dilation in humans: A methodological and physiological guideline. Am J Physiol Heart Circ Physiol. 2011;300:H2-H12.
35. Devin JK, Pretorius M, Nian H, Yu C, Billings FT 4th, Brown NJ. Substance P increases sympathetic activity during combined angiotensin-converting enzyme and dipeptidyl peptidase-4 inhibition. Hypertension. 2014;63:951-957.